Seasonality suggests November softness and December strength, yet select Pharma counters consistently outperform. Three stocks offering the favourable risk-reward from…
This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths to improve access to obesity…
India’s drug regulator (CDSCO) proposes ending the easy bioequivalence-only route for new generic drugs, potentially mandating expensive clinical trials to…
Indian pharma stocks, including Aurobindo Pharma and Lupin, surged after reports indicated the US Administration is considering excluding generic medicines…